Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell (e.g., Honey, Etc.) Patents (Class 424/172.1)
-
Patent number: 10202463Abstract: Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules.Type: GrantFiled: June 30, 2016Date of Patent: February 12, 2019Assignee: Thomas Jefferson UniversityInventors: Scott A. Waldman, Adam E. Snook, Michael S. Magee
-
Patent number: 10166251Abstract: The invention provides methods of inhibiting epigenetic gene silencing in a cell expressing NPM/ALK or decreasing NPM/ALK content in a cell, by contacting a cell with an agent capable of increasing the concentration of Stat5a protein or its functional analog. Further, the invention provides a method of treating malignancies expressing oncogenic kinase by administering to a patient affected with a malignancy an agent capable of increasing the concentration of Stat5a protein or its epigenetically silenced functional tumor suppressor analog in a malignant cell. Finally, it provides a method to diagnose malignancy and monitor patient's response to therapy by analysis of the degree of DNA methylation of the gene encoding for Stat5a or its analog, their mRNA, or protein.Type: GrantFiled: October 13, 2016Date of Patent: January 1, 2019Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Mariusz A. Wasik, Qian Zhang
-
Patent number: 10160805Abstract: Methods and compositions for treating inflammatory bowel disease by promoting mucosal healing in the gastrointestinal (GI) tract are encompassed herein. More particularly, methods and compositions described herein relate to agents that activate mononuclear phagocytes (MNPs) in the GI tract and, in turn, regulate the activity of interleukin (IL)-22-producing group 3 innate lymphoid cells (ILC3) in close proximity thereto.Type: GrantFiled: July 13, 2015Date of Patent: December 25, 2018Assignees: New York University, Cornell UniversityInventors: Randy S. Longman, Gretchen E. Diehl, Dan R. Littman
-
Patent number: 10144932Abstract: Methods of treating movement disorders by reducing the activity of Nurr1 are disclosed. These methods are particularly applicable to subjects suffering from Parkinson's disease who have either developed levodopa-induced dyskinesia (LID) or are at risk of developing LID. In some aspects, the invention relates to a method for treating a movement disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition, wherein said composition reduces the activity of a nuclea receptor related 1 protein (“Nurr1”). In some embodiments, the movement disorder is a dyskinesia. The movement disorder may be a levodopa-induced dyskinesia.Type: GrantFiled: June 5, 2015Date of Patent: December 4, 2018Assignee: Board of Trustees of Michigan State UniversityInventors: Fredric P. Manfredsson, Jack W. Lipton, Nicholas Kanaan, Timothy Collier, Kathy Steece-Collier, Caryl E. Sortwell
-
Patent number: 10137195Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.Type: GrantFiled: March 17, 2014Date of Patent: November 27, 2018Assignees: Ganymed Pharmaceuticals GmbH, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbHInventors: Ugur Sahin, Özlem Türeci
-
Patent number: 10058543Abstract: Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP) through the administration of a therapeutically effective amount of a Sphingosine-1-phosphate receptor type 2 (S1PR2) inhibitor.Type: GrantFiled: June 1, 2015Date of Patent: August 28, 2018Assignee: DALHOUSIE UNIVERSITYInventor: Christopher McMaster
-
Patent number: 10040855Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: GrantFiled: May 2, 2012Date of Patent: August 7, 2018Assignee: Millennium Pharmaceuticals, Inc.Inventors: Willow Diluzio, Phoung M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown
-
Patent number: 10035861Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: GrantFiled: November 24, 2014Date of Patent: July 31, 2018Assignee: Amgen Inc.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Patent number: 10035853Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.Type: GrantFiled: February 29, 2016Date of Patent: July 31, 2018Assignee: AbbVie Stemcentrx LLCInventors: William Robert Arathoon, Ishai Padawer, Luis Antonio Cano, Vikram Natwarsinhji Sisodiya, Karthik Narayan Mani, David Liu
-
Patent number: 10017475Abstract: Combretastatins analog compounds and their pharmaceutically acceptable salts are presented, as well as pharmaceutical compositions comprising the combretastatin analog compounds and uses of the combretastatin analog compounds, either alone or in combination with at least one additional therapeutic agent, in the treatment of cancer, and in particular cancer presenting as metastatic tumors.Type: GrantFiled: March 26, 2015Date of Patent: July 10, 2018Assignee: XAVIER UNIVERSITY OF LOUSIANAInventors: Guangdi Wang, Shilong Zheng, Qiu Zhong, Qiang Zhang
-
Patent number: 10004780Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD). In particular the present invention relates to RdCVFL polypeptide or polynucleotide for use in the treatment of AMD.Type: GrantFiled: October 17, 2013Date of Patent: June 26, 2018Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Thierry Leveillard, Jose-Alain Sahel, Therese Cronin, Leah Byrne, Ram Fridlich
-
Patent number: 9933439Abstract: Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich ?-2-glycoprotein (LRG); S100-A8 (calgranulin); ?-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-?-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and ?-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals.Type: GrantFiled: October 3, 2014Date of Patent: April 3, 2018Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Alex Kentsis, Hanno Steen, Richard Bachur
-
Patent number: 9890213Abstract: Methods for treating diseases associated with chemokine (C-X-C motif) ligand 13 (CXCL13) expression, including certain autoimmune and inflammatory diseases such as Sjogren's syndrome are provided herein. The methods comprise administering to a subject in need thereof an effective amount of an agent that inhibits CXCL13 activity. According to aspects of the invention illustrated herein, there is provided a method of treating, preventing, or reducing the exacerbation of a B-cell-mediated inflammatory condition in a subject, including administering to a subject an effective amount of an isolated binding molecule which specifically binds to CXCL13, wherein said molecule prevents or inhibits CXCL13 activity.Type: GrantFiled: March 1, 2013Date of Patent: February 13, 2018Assignee: Vaccinex, Inc.Inventors: Ernest S. Smith, Maurice Zauderer
-
Patent number: 9834607Abstract: Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.Type: GrantFiled: September 17, 2015Date of Patent: December 5, 2017Assignee: The Brigham and Women's Hospital, Inc.Inventors: Vijay K. Kuchroo, Ana C. Anderson
-
Patent number: 9816999Abstract: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.Type: GrantFiled: January 26, 2015Date of Patent: November 14, 2017Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal
-
Patent number: 9815898Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.Type: GrantFiled: May 15, 2017Date of Patent: November 14, 2017Assignees: Novartis AG, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
-
Patent number: 9771417Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.Type: GrantFiled: August 6, 2015Date of Patent: September 26, 2017Assignee: NOVARTIS AGInventors: John Trauger, Andrei Igorevich Voznesensky
-
Patent number: 9758594Abstract: The present invention relates to a multivalent antibody comprising multiple heavy chain variable regions of antibody linked to each other via a linker comprising an amino acid sequence encoding an immunoglobulin domain or a fragment thereof.Type: GrantFiled: April 27, 2009Date of Patent: September 12, 2017Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventor: Nobuaki Takahashi
-
Patent number: 9709563Abstract: Passivated substrates are provided for use in assays, comprising at least one covalently bonded ligand having specific binding activity for a molecule, and at least one covalently bonded blocking agent, wherein said ligand is directly bonded to the substrate surface. In certain embodiments, the ligand and blocking agent are covalently bonded only to the substrate surface, and not directly bonded to each other. In certain other embodiments, the ligand and blocking agent have at least one additional covalent bond to one another. Methods for preparing and using passivated substrates in bioassays are also provided.Type: GrantFiled: March 12, 2010Date of Patent: July 18, 2017Assignee: Agilent Technologies, Inc.Inventor: Roderick Nicholas Hobbs
-
Patent number: 9708590Abstract: The present invention provides the three-dimensional structure of human ?-N-acetylglucosaminidase (NAGLU) protein. This crystallographic information is useful in the identification and development of novel binding compounds of NAGLU, NAGLU mutants, for example, those associated with Sanfilippo syndrome type B (mucopolysaccharidosis III B (MPS III-B)), and other NAGLU family members (family 89 ?-N-acetylglucosaminidase) which may modulate the activity and/or stability of mutated NAGLU. Such compounds may be useful for the treatment of Sanfilippo syndrome type B (mucopolysaccharidosis III B (MPS III-B)).Type: GrantFiled: July 7, 2014Date of Patent: July 18, 2017Assignee: Shire Human Genetic Therapies, Inc.Inventors: Muthuraman Meiyappan, Michael F. Concino, Angela W. Norton
-
Patent number: 9688747Abstract: The present invention features methods and compositions for the generation and use of conformation-specific anti-bodies or fragments thereof.Type: GrantFiled: March 14, 2014Date of Patent: June 27, 2017Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Kun Ping Lu, Xiao Zhen Zhou
-
Patent number: 9683040Abstract: The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenesis effect in in-vivo models.Type: GrantFiled: April 26, 2013Date of Patent: June 20, 2017Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Yoshitaka Isumi, Toshiyuki Sato, Jun Hasegawa, Tatsuya Inoue
-
Patent number: 9623115Abstract: Disclosed herein are compositions and methods of use of dock and lock (DNL) complexes comprising a first antibody or fragment that binds to a stem cell antigen and a second antibody or fragment thereof that binds to an antigen on a diseased or damaged tissue or organ. The DNL complexes are of use for targeting stem cells to diseased or damaged organs or tissues and may be used to treat a variety of diseases or conditions that are responsive to stem cell therapy.Type: GrantFiled: November 14, 2011Date of Patent: April 18, 2017Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 9598733Abstract: Seven protective alleles for IgA nephropathy have been discovered that can be identified by analyzing a DNA sample for seven respective SNPs. A method is provided for identifying and treating subjects at risk of developing IgA neuropathy based on a new seven-SNP genetic risk score. Also provided are screening methods to identify compounds that bind to and reduce the expression or biological activity of a either CFHR1 or CFHR3.Type: GrantFiled: February 17, 2012Date of Patent: March 21, 2017Assignees: The Trustees of Columbia University in the City of New York, Yale UniversityInventors: Ali Gharvari, Krzysztof Kiryluk, Richard Lifton
-
Patent number: 9587032Abstract: The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor.Type: GrantFiled: July 11, 2013Date of Patent: March 7, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Joseph A. Mollick, Pearline Teo, Paul J. Utz
-
Patent number: 9574005Abstract: Addition of argininamide or valinamide to a highly concentrated antibody solution was found to lead to remarkable stabilization, in particular, stabilization against photostress.Type: GrantFiled: July 19, 2012Date of Patent: February 21, 2017Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Daisuke Kameoka, Masaya Yasutake
-
Patent number: 9562087Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.Type: GrantFiled: November 3, 2015Date of Patent: February 7, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Irving L. Weissman, Roy Louis Maute, Melissa N. McCracken, Sydney Gordon
-
Patent number: 9561290Abstract: The invention relates to new functionalized thieno-indole derivatives of formula (I) or (II) which have cytotoxic activity and are useful in treating diseases such as cancer and cellular proliferation disorders. The invention also relates to the use of these functionalized thieno-indole derivatives in the preparation of conjugates.Type: GrantFiled: March 28, 2013Date of Patent: February 7, 2017Assignee: NERVIANO MEDICAL SCIENCES S.R.L.Inventors: Italo Beria, Michele Caruso, Vittoria Lupi, Paolo Orsini, Matteo Salsa
-
Patent number: 9546206Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.Type: GrantFiled: August 7, 2015Date of Patent: January 17, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Irving L. Weissman, Roy Louis Maute, Melissa N. McCracken, Sydney Gordon
-
Patent number: 9486469Abstract: The invention provides methods of inhibiting epigenetic gene silencing in a cell expressing NPM/ALK or decreasing NPM/ALK content in a cell, by contacting a cell with an agent capable of increasing the concentration of Stat5a protein or its functional analog. Further, the invention provides a method of treating malignancies expressing oncogenic kinase by administering to a patient affected with a malignancy an agent capable of increasing the concentration of Stat5a protein or its epigenetically silenced functional tumor suppressor analog in a malignant cell. Finally, it provides a method to diagnose malignancy and monitor patient's response to therapy by analysis of the degree of DNA methylation of the gene encoding for Stat5a or its analog, their mRNA, or protein.Type: GrantFiled: September 29, 2008Date of Patent: November 8, 2016Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Mariusz A. Wasik, Qian Zhang
-
Patent number: 9393268Abstract: Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules.Type: GrantFiled: March 14, 2014Date of Patent: July 19, 2016Assignee: Thomas Jefferson UniversityInventors: Scott A. Waldman, Adam E. Snook, Michael S. Magee
-
Patent number: 9353188Abstract: Disclosed herein are novel compositions and methods for the inhibition of Plexin B2-mediated Angiogenin activity. Such compositions and methods are useful, for example, for the treatment of cancer, the treatment of wet AMD and the inhibition of angiogenesis. Also disclosed herein are methods of determining whether a test agent is a modulator of Plexin B2 activity.Type: GrantFiled: March 28, 2012Date of Patent: May 31, 2016Assignees: President and Fellows of Harvard College, Tufts Medical Center, Inc.Inventors: Guofu Hu, Wenhao Yu
-
Patent number: 9339526Abstract: Provided herein are FDC-SP polypeptides and methods of using such polypeptides. Methods include, but are not limited to, altering IgA concentration in a subject, treating a subject having signs of a disorder that includes excessive IgA production, identifying a compound that decreases the concentration of IgA in an animal, and identifying a compound that treats a condition associated with increased levels of IgA. Also provided herein is an animal that has decreased expression of an endogenous FDC-SP coding sequence. The animal may develop pathophysiological features of IgA nephropathy, and/or may display increased IgA in serum, saliva, bronchoalveolar lavage fluid, or a combination thereof; increased IgA expressing B lymphocytes in circulation, lymphoid tissue, or a combination thereof; or increased IgA production in vitro by isolated B lymphocytes.Type: GrantFiled: January 17, 2012Date of Patent: May 17, 2016Assignee: UNIVERSITY OF MANITOBAInventors: Aaron Marshall, Sen Hou
-
Patent number: 9250250Abstract: The invention provides methods of diagnosing or determining a cause of an autoimmune encephalitis or an epilepsy in a subject and of diagnosing a tumor in a subject, comprising the step of testing a biological sample of the subject for an antibody to LGI1. This invention further provides methods of treating an autoimmune encephalitis or an epilepsy, comprising the steps of detecting an antibody to LGI1 and treating a tumor associated with the disease.Type: GrantFiled: May 11, 2011Date of Patent: February 2, 2016Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventor: Josep Dalmau
-
Patent number: 9248181Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.Type: GrantFiled: April 19, 2013Date of Patent: February 2, 2016Assignee: Merus B.V.Inventors: Cornelis A. De Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
-
Patent number: 9102732Abstract: Disclosed are immunological compositions and methods for reducing activity of glucagon signaling using antibodies against glucagon receptor.Type: GrantFiled: September 8, 2009Date of Patent: August 11, 2015Assignee: NEOPHARM CO., LTD.Inventors: Eunkyung Lee, Seong-Kyung Seo, Tae-Seong Kim
-
Patent number: 9080183Abstract: The current invention reports a promoter having the nucleic acid sequence of SEQ ID NO: 02, or SEQ ID NO: 03, or SEQ ID NO: 04, or SEQ ID NO: 06, which is a 5? shortened SV40 promoter with reduced promoter strength especially useful for the limited expression of heterologous polypeptides or selectable markers.Type: GrantFiled: June 25, 2008Date of Patent: July 14, 2015Assignee: HOFFMANN-LA ROCHE INC.Inventors: Christian Klein, Erhard Kopetzki
-
Patent number: 9078879Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.Type: GrantFiled: August 23, 2013Date of Patent: July 14, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Karl-Heinz Heider, Eric Borges, Elinborg Ostermann
-
Patent number: 9080149Abstract: The present invention provides the use of the cell surface antigen CD51 as a negative selection marker for neuronal cells and a method for enrichment, isolation and/or detection of neuronal cells comprising the steps a) contacting a sample containing neuronal cells with an antigen-binding fragment specific for the CD51 antigen coupled to a solid phase, thereby labeling the CD51 positive cells of said sample and b) isolating the non-labeled cells of said sample.Type: GrantFiled: February 27, 2013Date of Patent: July 14, 2015Assignee: Miltenyi Biotec GmbHInventors: Andreas Bosio, Melanie Jungblut
-
Patent number: 9075045Abstract: An assay system designed to detect a protein biomarker in urine that is diagnostic for interstitial cystitis (IC). The presence of a 9 amino acid glycopeptide, antiproliferative factor (APF), in urine is unique to patients with IC. Urine samples from patients who exhibit symptoms consistent with IC are added to the assay system. Binding of APF to the cytoskeletal associated protein 4 (CKAP4) is positive for the presence of APF in urine and diagnostic for IC. The diagnostic system is a significant and surprising advance in diagnosis of IC and has commercial applications relevant to women and men who suffer from symptoms consistent with IC.Type: GrantFiled: June 6, 2013Date of Patent: July 7, 2015Assignees: The Commonwealth Medical College, University of Florida Research Foundation, Inc.Inventors: David Alan Zacharias, Sonia Lobo Planey
-
Publication number: 20150147322Abstract: The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor ? (IL-3R?) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.Type: ApplicationFiled: February 9, 2015Publication date: May 28, 2015Inventors: Gino Luigi VAIRO, Andrew NASH, Eugene MARASKOVSKY, Nick WILSON, Samantha BUSFIELD, Con PANOUSIS
-
Publication number: 20150147343Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.Type: ApplicationFiled: July 2, 2014Publication date: May 28, 2015Applicant: University of ZurichInventors: Roger NITSCH, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
-
Publication number: 20150140015Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of pancreatic cancers. In particular, the present invention relates to an OX1R agonist for use in the treatment of pancreatic cancer in a subject in need thereof.Type: ApplicationFiled: January 20, 2015Publication date: May 21, 2015Inventor: Thierry VOISON
-
Publication number: 20150140014Abstract: A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.Type: ApplicationFiled: November 15, 2013Publication date: May 21, 2015Applicant: Samsung Electronics Co., Ltd.Inventors: Seung Hyun LEE, Geun Woong Kim, Kyung Ah Kim, Hye Won Park, Ho Yeong Song, Young Mi Oh, Saet Byoul Lee, Ji Min Lee, Kwang Ho Cheong, Yun Ju Jeong, Mi Young Cho, Jae Hyun Choi, Yun Jeong Song, Yoon Aa Choi
-
Publication number: 20150140016Abstract: The present invention is drawn to understanding lytic bone diseases. In this regard, the present invention discloses mechanism by which Wnt signaling antagonist inhibits bone differentiation. Also disclosed herein are methods for treating multiple myeloma, for restoring osteoprotegerin (OPG) expression in a cell, for inhibiting receptor activator of nuclear factor kappa B ligand (RANKL) expression in a cell, and for increasing bone mass in a subject. These methods utilize a DKK1 neutralizing antibody, an anti-sense oligonucleotide against a DKK1 gene, or a shRNA against a DKK1 gene to inhibit the activity of the DKK1 protein.Type: ApplicationFiled: January 30, 2015Publication date: May 21, 2015Applicant: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSASInventors: John D. Shaughnessy, JR., Bart Barlogie, Ya-Wei Qiang
-
Publication number: 20150140009Abstract: The invention provides methods for the treatment of radiation exposure featuring agents that interfere with the expression, production, release, accumulation, or activity of a TNF?, IL6, EGF, IL1-alpha, IL1-beta, G-CSF, MCP-1, MIP-1, SCF, or RANTES receptor; or a TNF-?, IL6, EGF, IL1-alpha, IL1-beta, G-CSF, MCP-1, MIP-1, SCF, or RANTES peptide or fragment thereof.Type: ApplicationFiled: August 19, 2014Publication date: May 21, 2015Inventor: David A. Goukassian
-
Publication number: 20150140004Abstract: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.Type: ApplicationFiled: December 16, 2014Publication date: May 21, 2015Applicant: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.Inventors: MICHAEL C. MULLENIX, ROBERT ELLIOT ZIPKIN, JEFFREY KROLL ADAMS, WAYNE FORREST PATTON, JAMES J. DONEGAN
-
Publication number: 20150132289Abstract: A method or composition comprising an anti-CD3 immune molecule for treatment of PSC (primary sclerosing cholangitis) or PBC (primary biliary cirrhosis) in a subject.Type: ApplicationFiled: February 23, 2013Publication date: May 14, 2015Inventors: Ronald Ellis, Yaron Ilan, Nadya Lisovoder, Shahar Dotan
-
Publication number: 20150132370Abstract: Embodiments of the present disclosure are directed to methods of treating, reducing or preventing fibrosis or scarring including administering a therapeutic molecular agent selected from the group consisting of an agent that inhibits chaperonin containing T-complex polypeptide subunit eta polypeptide (“CCT-eta”), an agent that inhibits ?-Smooth Muscle Actin (“?-SMA”), or a combination thereof. In embodiments, the fibrosis may include Dupuytren's contracture, Peyronie's disease, pulmonary fibrosis, cirrhosis, interstitial lung disease or scarring alopecia.Type: ApplicationFiled: January 5, 2015Publication date: May 14, 2015Inventor: Sandeep Kathju
-
Publication number: 20150132321Abstract: The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis. Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via ?1 integrin activation.Type: ApplicationFiled: November 7, 2014Publication date: May 14, 2015Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Donald E. Ingber, Charles K. Thodeti